The growth of tumor in both CD4+ and CD8+ T cell depletion groups increased faster than treated group (Fig. 5C–E), leading to diminished immunotherapy efficiency as determined by survival analysis (Fig. 5F–G). The gene discussed is CD8A; the disease is neoplasm.